Intermittent Injectable Program
Obesity
PreclinicalActive
Key Facts
About MitoRx Therapeutics
MitoRx Therapeutics is a preclinical-stage biotech pioneering a novel approach to cardiometabolic disease by targeting mitochondrial dysfunction. Its core technology, the mtH2SD platform, uses small molecules designed to enzymatically release hydrogen sulfide within mitochondria to restore sulfide-signaling and reverse metabolic defects. The company is advancing two initial obesity programs—one intermittent injectable and one oral—with the goal of entering clinical trials. Led by an experienced team with a strong academic foundation from Prof. Matt Whiteman, MitoRx is positioning itself in the large obesity market with a differentiated mechanism aimed at quality of weight loss.
View full company profileTherapeutic Areas
Other Obesity Drugs
| Drug | Company | Phase |
|---|---|---|
| LET003 | Harbour BioMed | Discovery |
| LET001 | Harbour BioMed | Discovery |
| RGT-075 | Regor Therapeutics | Phase 2b |
| Anti‑Obesity Oral Drug | Premas Biotech | Phase 1 |
| Obesity Target Discovery Collaboration | Fauna Bio | Target Discovery/Preclinical |
| GLP-1 variants | Heligenics | Discovery |
| MYO Platform (Metabolic Disease) | Renbio | Pre-clinical |
| Obesity Clinical Trials | IMA Clinical Research | Not Applicable (Service) |
| KAYO-2000 | KayoThera | Preclinical |
| MVD-1 (SANA) | Eolo Pharma | Phase 1 |
| GIP-neutralizing antibody | Helicore Biopharma | Pre-clinical |
| Antral Gastroplasty / Endoscopic Sleeve | Endo-TAGSS | Pre-clinical |